Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome
NCT01622049 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77
Last updated 2013-03-14
Summary
Patients undergo a detailed ultrasound examination to rule out the presence of congenital anomalies, and to assess the hemodynamic status of the fetuses. Patients with confirmed TTTS will be considered candidates for the trial. Patients will be counseled about the risks and benefits of all treatment options and will be free to choose any treatment option. They will then be asked to sign an informed consent. The procedure will be performed under local anesthesia. After a 2-3 mm skin incision, and under ultrasound guidance, the trocar will be introduced in the amniotic cavity of the Recipient twin. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. An accessory port may be required in some cases. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted often during the procedure. An amniodrainage of the larger sac may be performed at the time of the procedure. The patient will remain hospitalized 1-3 days and will undergo an ultrasound assessment on the first post operative day. Patients will undergo a weekly ultrasound examination for four weeks after the initial therapeutic procedure. Sonographic parameters to evaluate will include: maximum vertical pocket of fluid in each sac, visualization of the fetal bladders, absence or presence of hydrops, and Doppler studies of the umbilical artery, umbilical vein, ductus venosus, and middle cerebral artery. After delivery babies will be assessed by their corresponding neonatologists or pediatricians. Infants admitted to the neonatal intensive care unit will be followed through their discharge. Evidence of neurological or cardiac morbidity will be sought in each twin. If either of these complications is suspected, evaluation by pediatric neurology or pediatric cardiology will be requested. Babies will be followed up for neonatal, infant and childhood morbidity or mortality. It is requested that all placentas be delivered fresh to Tampa General Hospital in an icebox container for assessment. Placentas will be discarded after analysis.
Conditions
- Twin Twin Transfusion Syndrome
Interventions
- DEVICE
-
Selective Laser Photocoagulation of Communicating Vessels
Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
Sponsors & Collaborators
-
University of South Florida
lead OTHER
Principal Investigators
-
Ruben A Quintero, MD · University of South Florida
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-10-31
- Primary Completion
- 2009-02-28
- Completion
- 2009-02-28
Countries
- United States
Study Locations
More Related Trials
-
Feto-Fetal Transfusion Syndrome in Multiple Pregnancies
NCT04148859 ·Status: RECRUITING ·Phase: NA
-
Renal Artery Dopplers in Twin Twin Transfusion Syndrome
NCT03449823 ·Status: COMPLETED
-
The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence
NCT04432168 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery
NCT03425799 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of Topical and Intravenous Tranexamic Acid in Surgical Treatment of Lumbar Degenerative Disease
NCT02496364 ·Status: WITHDRAWN ·Phase: NA
-
Fibrinogen Concentrate In Children After Cardiac Surgery
NCT01187225 ·Status: COMPLETED ·Phase: PHASE2
-
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures
NCT00233246 ·Status: WITHDRAWN ·Phase: PHASE3
-
Fibrinogen Early In Severe Trauma StudY II
NCT05449834 ·Status: RECRUITING ·Phase: PHASE3
-
Fibrinogen Early In Severe Trauma studY Junior
NCT03508141 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Topical Versus Intravenous Tranexamic Acid in Controlling Blood Loss
NCT06188052 ·Status: RECRUITING ·Phase: PHASE4
-
Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery
NCT02063035 ·Status: COMPLETED ·Phase: PHASE4
-
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage
NCT05554211 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty
NCT02504125 ·Status: COMPLETED ·Phase: PHASE4
-
Fibrinogen Early In Severe Trauma studY
NCT02745041 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Idiopathic Scoliosis Treated With Tranexamic Acid
NCT01089140 ·Status: TERMINATED ·Phase: PHASE2
-
Local Subfascial and Intramuscular Tranexamic Acid Administration in Pediatric Patient Undergoing Scoliosis Surgery, Double Blind Randomized Control Trial
NCT04622397 ·Status: UNKNOWN ·Phase: NA
-
Predicting Lung Injury From Transfusion in Patients With Liver Disease
NCT01756690 ·Status: TERMINATED
-
The Efficacy of the Administration of Fibrinogen in Liver Transplantation
NCT01539057 ·Status: UNKNOWN ·Phase: PHASE3
-
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
NCT06014320 ·Status: UNKNOWN
-
Fibrinogen in Liver Transplant Subjects
NCT06764927 ·Status: WITHDRAWN ·Phase: PHASE4
-
Intravenous Tranexamic Acid During Rhytidectomy
NCT03970213 ·Status: UNKNOWN ·Phase: PHASE4
-
Effectiveness of a Intraoperative Blood Recovery System in Cardiovascular Surgery in Brazil
NCT06601582 ·Status: RECRUITING ·Phase: NA
-
Tranexamic Acid for Craniofacial Surgery
NCT00722436 ·Status: TERMINATED ·Phase: PHASE4
-
Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy
NCT06582420 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery
NCT01728636 ·Status: COMPLETED ·Phase: PHASE2